Christopher Cutie, MD, of Johnson & Johnson Innovative Medicine, describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery of gemcitabine to improve outcomes and preserve patients' bladders. Dr. Cutie explains how advancements like the TAR-200 system, offering 24/7 localized therapy, are redefining standards for patient care. Dr. Cutie also highlights strategies to manage treatment-related side effects and maintain quality of life, alongside insights into the science behind TAR-200's 84% complete response rate.
Watch more expert video insights at https://www.guoncologynow.com.
#bladdercancer #cancer #oncology #urology
Watch more expert video insights at https://www.guoncologynow.com.
#bladdercancer #cancer #oncology #urology
- Category
- Urology

Be the first to comment